TY  - JOUR
A1  - Schäfer, Richard
A1  - Spohn, Gabriele
A1  - Bechtel, Marco
A1  - Bojkova, Denisa
A1  - Baer, Patrick C.
A1  - Kuçi, Selim
A1  - Seifried, Erhard
A1  - Ciesek, Sandra
A1  - Cinatl, Jindrich
T1  - Human mesenchymal stromal cells are resistant to SARS-CoV-2 infection under steady-state, inflammatory conditions and in the presence of SARS-CoV-2-infected cells
T2  - Stem cell reports
N2  - Previous studies reported on the safety and applicability of mesenchymal stem/stromal cells (MSCs) to ameliorate pulmonary inflammation in acute respiratory distress syndrome (ARDS). Thus, multiple clinical trials assessing the potential of MSCs for COVID-19 treatment are underway. Yet, as SARS-inducing coronaviruses infect stem/progenitor cells, it is unclear whether MSCs could be infected by SARS-CoV-2 upon transplantation to COVID-19 patients. We found that MSCs from bone marrow, amniotic fluid, and adipose tissue carry angiotensin-converting enzyme 2 and transmembrane protease serine subtype 2 at low levels on the cell surface under steady-state and inflammatory conditions. We did not observe SARS-CoV-2 infection or replication in MSCs at steady state under inflammatory conditions, or in direct contact with SARS-CoV-2-infected Caco-2 cells. Further, indoleamine 2,3-dioxygenase 1 production in MSCs was not impaired in the presence of SARS-CoV-2. We show that MSCs are resistant to SARS-CoV-2 infection and retain their immunomodulation potential, supporting their potential applicability for COVID-19 treatment.
KW  - SARS-CoV-2
KW  - COVID-19
KW  - mesenchymal stromal cells
KW  - inflammation
KW  - ARDS
KW  - stem cells
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/77959
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-779592
SN  - 2213-6711
VL  - 16.2021
IS  - 3
SP  - 419
EP  - 427
PB  - Elsevier
CY  - Amsterdam
ER  -